Chapter overview: Inborn errors of metabolism provide a capstone for the central dogma. A DNA variant can alter an enzyme, block a pathway, produce substrate accumulation or product deficiency, and create a clinical emergency. The chapter uses the supplied MCAD case and source-book disorder profiles to trace that logic.
Learning Objectives
Define an .
Trace the gene-to-enzyme-to-metabolite chain.
Distinguish substrate accumulation from product deficiency.
Explain the MCAD fasting-risk logic in the supplied transcript.
Use a structured pathway analysis across several source-book disorders.
Metabolic pathway logic and disorders
Inborn errors of metabolism (IEMs) are a group of genetic conditions that arise from defects in enzymes or pathways critical for breaking down or processing nutrients. These disorders often manifest early in life, sometimes in the neonatal period, and can cause life-threatening complications if not diagnosed and treated quickly. In this chapter, we will explore key IEMs using real-world case-inspired narratives and a structured scientific breakdown of what is defective, what accumulates, what is deficient, and the physiological consequences of these disruptions.
Introduction: The Origins of Inborn Errors of Metabolism
In 1934, a determined Norwegian mother noticed something unusual about her two children. Both showed signs of developmental delay and intellectual disability, but what perplexed her most was the odd, musty odor of their urine. Believing the symptoms to be linked, she sought help. Eventually, she found Dr. Asbjørn Følling, a metabolic specialist and chemist who was fascinated by her story. Dr. Følling analyzed the children's urine and, after weeks of daily testing, identified phenylpyruvic acid,an abnormal compound. He soon linked it to a condition he called "imbecillitas phenylpyruvica," now known as phenylketonuria (PKU).
Følling expanded his search, testing 430 individuals with intellectual impairments. Eight had the same compound in their urine and similar physical traits, including pale skin and eczema. From their family histories, Følling inferred a recessive inheritance pattern. This was one of the first demonstrations of how a single metabolic defect could cause wide-ranging systemic issues.
Later, Dr. Jervis proposed that an enzyme deficiency might be responsible for the buildup of phenylpyruvic acid. This idea changed everything. Soon after, studies showed that dietary restriction of phenylalanine dramatically improved patient outcomes. By the 1960s, thanks to Dr. Robert Guthrie,who developed a newborn screening test influenced by personal family experience,PKU could be detected shortly after birth, allowing early treatment. PKU became the model for understanding hundreds of other metabolic disorders.